title: Effect of moxifloxacin combined with cefotaxime compared to cefotaxime-gentamicin combination on prevention of white matter damage associated with Escherichia coli sepsis in neonatal rats.
abstract: Relative to the cefotaxime-gentamicin combination, the moxifloxacin-cefotaxime combination significantly reduced microglial activation and immature oligodendrocyte cell death and delayed myelination in the developing white matter of neonatal rats with experimental Escherichia coli sepsis. These neuroprotective effects were not due to differences in in vivo bactericidal activities or in the systemic inflammatory responses and could be related to the intrinsic immunomodulatory properties of moxifloxacin. Molecular mechanisms underlying the neuroprotective effect of moxifloxacin remain to be elucidated.
authors.affiliation: Université Paris Diderot, Equipe d'Accueil EA 3105, F-75019 Paris, France.
authors.forename: Nolwenn
authors.initials: N
authors.lastname: Le Saché
authors.forename: Olivier
authors.initials: O
authors.lastname: Baud
authors.forename: Julien
authors.initials: J
authors.lastname: Pansiot
authors.forename: Hoa
authors.initials: H
authors.lastname: Pham
authors.forename: Valérie
authors.initials: V
authors.lastname: Biran
authors.forename: Nadège
authors.initials: N
authors.lastname: Brunel-Meunier
authors.forename: Philippe
authors.initials: P
authors.lastname: Bidet
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Kitzis
authors.forename: Pierre
authors.initials: P
authors.lastname: Gressens
authors.forename: Edouard
authors.initials: E
authors.lastname: Bingen
authors.forename: Christiane
authors.initials: C
authors.lastname: Charriaut-Marlangue
authors.forename: Stéphane
authors.initials: S
authors.lastname: Bonacorsi
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D002439:Cefotaxime / Q000627:therapeutic use*; D004927:Escherichia coli Infections / Q000188:drug therapy*; D024841:Fluoroquinolones; D005839:Gentamicins / Q000627:therapeutic use*; D056784:Leukoencephalopathies / Q000382:microbiology* / Q000517:prevention & control*; D000077266:Moxifloxacin; D011804:Quinolines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000188:drug therapy*
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D005839:Gentamicins; D011804:Quinolines; D002439:Cefotaxime; D000077266:Moxifloxacin